BSR Intelligence

Daily intelligence on the peptide research industry.

Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.

All Regulatory & Policy Pharma & GLP-1 Research Pipeline Industry & Community Reputational Risks BSR Insights

Pharma & GLP-1

Wegovy oral pill claims early US lead over Lilly's Foundayo as Novo Nordisk Q1 results approach

Novo Nordisk's oral semaglutide pill (FDA-approved December 2025) and Eli Lilly's orforglipron (Foundayo, approved 1 April 2026) are now competing head-to-head in the US oral GLP-1 market. Cross-trial data favours Wegovy on weight loss; Foundayo has a usability edge. UK launch timing is unclear pending MHRA review.

05 May 2026